Regulus Therapeutics Inc.
RGLS
Rangering i aksjer
#17368
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aksjekurs
$8.16
Sist synkronisert: 2025-06-26
Markedsverdi
$234.57M
Endring (1 dag)
0.00%
Endring (1 år)
-88.86%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Markedsverdi av Regulus Therapeutics Inc.(RGLS)
Markedsverdi: $234.57M
Per October 2026 har Regulus Therapeutics Inc. en markedsverdi på $234.57M. Dette gjør Regulus Therapeutics Inc. til det 17368th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Regulus Therapeutics Inc. fra 2010 til 2026
RGLS sammenlignet med topp 5 mest populære stocks
